Association of CETP Gene Variants with Atherogenic Dyslipidemia Among Thai Patients Treated with Statin

References

• Arnett DK, Blumenthal RS, Albert MA, et al. ACC/AHA guideline on the primary prevention of cardiovascular disease a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019;2019(140):e596–e646.
   Google Scholar
• Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001;5:378–387. doi:10.1111/j.1582-4934.2001.tb00172.x
   PubMed Web of Science ®Google Scholar
• Ference BA, Yoo W, Alesh I. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a mendelian randomization analysis. J Am Coll Cardiol. 2012;60:2631–2639. doi:10.1016/j.jacc.2012.09.017
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists’ (CTT) collaborators: efficacy and safety of cholesterol‐lowering treatment: prospective meta‐analysis of data from 90056 participants in 14 randomised trials of statins. Lancet. 2005;336:1267–1278.
   Google Scholar
• Mihaylova B, Emberson J, Blackwell L, et al.; Cholesterol Treatment Trialists’ (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta‐analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–590.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380:565–571. doi:10.1016/S0140-6736(12)61190-8
   PubMed Web of Science ®Google Scholar
• Davies JT, Delfino SF, Feinberg CE, et al. Current and emerging uses of statins in clinical therapeutics: a review. Lipid Insights. 2016;9:13–29. doi:10.4137/LPI.S37450
   PubMedGoogle Scholar
• Akyea RK, Kai J, Qureshi N, et al. Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease. Heart. 2019;105:975–981. doi:10.1136/heartjnl-2018-314253
   Web of Science ®Google Scholar
• Rana JS, Liu JY, Moffet HH, et al. Metabolic dyslipidemia and risk of coronary heart disease in 28,318 adults with diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dl. Am J Cardiol. 2015;116:1700–1704.
   PubMed Web of Science ®Google Scholar
• Nichols GA, Philip S, Reynolds K, et al. Increased cardiovascular risk in Hypertriglyceridemic patients with statin-controlled LDL cholesterol. J Clin Endocrinol Metab. 2018;103:3019–3027. doi:10.1210/jc.2018-00470
   PubMed Web of Science ®Google Scholar
• Lawler PR, Akinkuolie AO, Chu AY, et al. Atherogenic lipoprotein determinants of cardiovascular disease and residual risk among individuals with low low-density lipoprotein cholesterol. J Am Heart Assoc. 2017;6:e005549. doi:10.1161/JAHA.117.005549
   Web of Science ®Google Scholar
• Nichols GA, Philip S, Reynolds K, et al. Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol. Diabetes Obes Metab. 2019;21:366–371.
   PubMed Web of Science ®Google Scholar
• Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115:450–458. doi:10.1161/CIRCULATIONAHA.106.637793
   PubMed Web of Science ®Google Scholar
• Barter PJ, Brewer HB Jr, Chapman MJ, et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23:160–167. doi:10.1161/01.ATV.0000054658.91146.64
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Goff WL, Guerin M, et al. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J. 2010;31:149–164.
   PubMed Web of Science ®Google Scholar
• Guerin M, Lassel TS, Goff WL, et al. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol. 2000;20:189–197. doi:10.1161/01.ATV.20.1.189
   PubMed Web of Science ®Google Scholar
• Karalis IK, Bergheanu SC, Wolterbeek R, et al. Effect of increasing doses of rosuvastatin and atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters. Curr Med Res Opin. 2010;26:2301–2313. doi:10.1185/03007995.2010.509264
   PubMed Web of Science ®Google Scholar
• Ference BA, Kastelein JJP, Ginsberg HN, et al. Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk. JAMA. 2017;318:947–956. doi:10.1001/jama.2017.11467
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Orsoni A, Robillard P, et al. Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: quantity vs quality over time and implication of CETP. J Clin Lipidol. 2018;12:784–800.
   Web of Science ®Google Scholar
• Blauw LL, Li-Gao R, Noordam R, et al. CETP (cholesteryl ester transfer protein) concentration: a genome-wide association study followed by Mendelian randomization on coronary artery disease. Circ Genom Precis Med. 2008;11:e002034.
   Google Scholar
• Thompson A, Di Angelantonio E, Sarwar N, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 2008;299:2777–2788. doi:10.1001/jama.299.23.2777
   PubMed Web of Science ®Google Scholar
• Schierer A, Been LF, Ralhan S, et al. Genetic variation in cholesterol ester transfer protein, serum CETP activity, and coronary artery disease risk in Asian Indian diabetic cohort. Pharmacogenet Genomics. 2012;22:95–104. doi:10.1097/FPC.0b013e32834dc9ef
   Web of Science ®Google Scholar
• Ordovas JM, Cupples LA, Corella D, et al. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler Thromb Vasc Biol. 2000;20:1323–1329. doi:10.1161/01.ATV.20.5.1323
   PubMed Web of Science ®Google Scholar
• Su Y, Wu K, Zhang Y, et al. Association between CETP I405 V polymorphism and hypertension in Hainan Han population. J Chin Gerontol. 2016;36:4458–4459.
   Google Scholar
• Schechter CB, Barzilai N, Crandall JP, et al. Cholesteryl ester transfer protein (CETP) genotype and reduced CETP levels associated with decreased prevalence of hypertension. Mayo Clin Proc. 2010;85:522. doi:10.4065/mcp.2009.0594
   Web of Science ®Google Scholar
• Li H, Xiao H, Zhang Y, et al. Relationship between CETP gene polymorphism and type 2 diabetes in Uygur. Chin Public Health. 2009;25:1430–1432.
   Google Scholar
• Inazu A, Brown ML, Hesler CB, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med. 1990;323:1234–1238. doi:10.1056/NEJM199011013231803
   PubMed Web of Science ®Google Scholar
• Cai G, Shi G, Huang Z. Gender specific effect of CETP rs708272 polymorphism on lipid and atherogenic index of plasma levels but not on the risk of coronary artery disease: a case–control study. Medicine. 2018;49:e13514. doi:10.1097/MD.0000000000013514
   Web of Science ®Google Scholar
• McCaffery JM, Ordovas JM, Huggins GS, et al. Weight gain prevention buffers the impact of CETP rs3764261 on high density lipoprotein cholesterol in young adulthood: the Study of Novel Approaches to Weight Gain Prevention (SNAP). Nutr Metab Cardiovasc Dis. 2018;28:816–821. doi:10.1016/j.numecd.2018.02.018
   Web of Science ®Google Scholar
• Guo S, Hu Y, Ding Y, et al. Association between eight functional polymorphisms and haplotypes in the Cholesterol Ester Transfer Protein (CETP) gene and dyslipidemia in national minority adults in the Far West Region of China. Int J Environ Res Public Health. 2015;12:15979–15992. doi:10.3390/ijerph121215036
   Web of Science ®Google Scholar
• Hou H, Ma R, Guo H, et al. Association between six CETP polymorphisms and metabolic syndrome in Uyghur adults from Xinjiang, China. Int J Environ Res Public Health. 2017;14:653.
   Web of Science ®Google Scholar
• Kooner JS, Chambers JC, Aguilar‐Salinas CA, et al. Genome‐wide scan identifies variation in MLXIPL associated with plasma triglycerides. Nat Genet. 2008;40:149–151. doi:10.1038/ng.2007.61
   PubMed Web of Science ®Google Scholar
• Lu Y, Tayebi N, Li H, et al. Association of CETP Taq1B and ´629C > A polymorphisms with coronary artery disease and lipid levels in the multi-ethnic Singaporean population. Lipids Health Dis. 2013;12:1–13. doi:10.1186/1476-511X-12-85
   Web of Science ®Google Scholar
• Wang X, Magkos F, Mittendorfer B. Sex differences in lipid and lipoprotein metabolism: it’s not just about sex hormones. J Clin Endocrinol Metab. 2011;96:885–893.
   PubMed Web of Science ®Google Scholar
• Puangpetch A, Srisawasdi P, Unaharassamee W, et al. Association between polymorphisms of LEP, LEPR, DRD2, HTR2A and HTR2C genes and risperidone- or clozapine-induced hyperglycemia. Pharmgenomics Pers Med. 2019;12:155–166.
   PubMed Web of Science ®Google Scholar
• Hoefner DM, Hodel SD, O’Brien JF, et al. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin Chem. 2001;47:266–274. doi:10.1093/clinchem/47.2.266
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419. doi:10.1007/BF00280883
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421.
   PubMed Web of Science ®Google Scholar
• Ahnadi CE, Berthezene F, Ponsin G. Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins in normolipidemic subjects. Atherosclerosis. 1993;99:219–228. doi:10.1016/0021-9150(93)90024-O
   PubMed Web of Science ®Google Scholar
• Guerin M, Egger P, Soudant C, et al. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis. 2002;163:287–296. doi:10.1016/S0021-9150(02)00037-0
   PubMed Web of Science ®Google Scholar
• Kuivenhoven JJW, Zwinderman AH, et al. The role of a commJAon variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med. 1998;338:86–93. doi:10.1056/NEJM199801083380203
   PubMed Web of Science ®Google Scholar
• Postmus I, Warren HR, Trompet S, et al. Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. J Med Genet. 2016;53:835–845. doi:10.1136/jmedgenet-2016-103966
   Web of Science ®Google Scholar
• Carlquist JF, Muhlestein JB, Horne BD, et al. The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease. Am Heart J. 2003;146:1007–1014. doi:10.1016/S0002-8703(03)00501-5
   PubMed Web of Science ®Google Scholar
• Wang J, Wang LJ, Zhong Y, et al. CETP gene polymorphisms and risk of coronary atherosclerosis in a Chinese population. Lipids Health. 2013;12;176.
   Web of Science ®Google Scholar
• Whiting BM, Anderson JL, Muhlestein JB, et al. Candidate gene susceptibility variants predict intermediate end points but not angiographic coronary artery disease. Am Heart J. 2005;150:243–250. doi:10.1016/j.ahj.2004.08.034
   Web of Science ®Google Scholar
• Niu W, Qi Y. Circulating cholesteryl ester transfer protein and coronary heart disease: mendelian randomization meta-analysis. Circ Cardiovasc Genet. 2015;8:114–121. doi:10.1161/CIRCGENETICS.114.000748
   Google Scholar
• Kark JD, Sinnreich R, Leitersdorf E, et al. Taq1B CETP polymorphism, plasma CETP, lipoproteins, apolipoproteins and sex differences in a Jewish population sample characterized by low HDL-cholesterol. Atherosclerosis. 2000;151:509–518. doi:10.1016/S0021-9150(99)00408-6
   Web of Science ®Google Scholar
• Ellman N, Keswell D, Collins M, et al. Ethnic differences in the association between lipid metabolism genes and lipid levels in black and white South African women. Atherosclerosis. 2015;240:311–317. doi:10.1016/j.atherosclerosis.2015.03.027
   Web of Science ®Google Scholar
• Heilbronn LK, Noakes M, Clifton PM. Association between HDL cholesterol and the Taq1B polymorphism in the cholesterol ester transfer protein gene in obese women. Atherosclerosis. 2002;162:419–424. doi:10.1016/S0021-9150(01)00733-X
   Web of Science ®Google Scholar
• Semaev S, Shakhtshneider E, Orlov P, et al. Association of RS708272 (CETP Gene Variant) with lipid profile parameters and the risk of myocardial infarction in the white population of western Siberia. Biomolecules. 2019;9:739. doi:10.3390/biom9110739
   Web of Science ®Google Scholar
• Nakamura A, Niimura H, Kuwabara K, et al. Gene-gene combination effect and interactions among ABCA1, APOA1, SR-B1, and CETP polymorphisms for serum high-density lipoprotein-cholesterol in the Japanese population. PLoS One. 2013;8:e82046.
   Web of Science ®Google Scholar
• Millwood IY, Bennett DA, Holmes MV, et al. China Kadoorie Biobank Collaborative Group. Association of CETP gene variants with risk for vascular and nonvascular diseases among Chinese adults. JAMA Cardiol. 2018;3:34–43. doi:10.1001/jamacardio.2017.4177
   Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M, et al. ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–2122. doi:10.1056/NEJMoa0706628
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Olsson AG, Abt M, dal-OUTCOMES Investigators, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 367;2012:2089–2099. doi:10.1056/NEJMoa1206797
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Nicholls SJ, Riesmeyer JS, ACCELERATE Investigators, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med. 376;2017:1933–1942. doi:10.1056/NEJMoa1609581
   PubMed Web of Science ®Google Scholar
• Bowman L, Hopewell JC, Chen F, et al.; HPS3/TIMI55–REVEAL Collaborative Group. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377:1217–1227.
   PubMed Web of Science ®Google Scholar